P/E ratio for Spectrum Pharmaceuticals (SPPI)

P/E ratio history for Spectrum Pharmaceuticals from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Johnson & Johnson JNJ	29.6	-1,135.13%	🇺🇸 USA
Novartis NVS	21.2	-840.23%	🇨🇭 Switzerland
Pfizer PFE	37.0	-1,393.20%	🇺🇸 USA
Abbott Laboratories ABT	31.0	-1,183.81%	🇺🇸 USA
Biogen BIIB	39.2	-1,471.11%	🇺🇸 USA
Bristol-Myers Squibb BMY	13.5	-573.15%	🇺🇸 USA
GSK plc GSK	14.8	-615.69%	🇬🇧 UK
Seagen SGEN	-57.0	1,893.72%	🇺🇸 USA
Curis CRIS	-0.0584	-97.96%	🇺🇸 USA
Teva Pharmaceutical Industries TEVA	62.4	-2,280.86%	🇮🇱 Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.